Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia

Detalles Bibliográficos
Autores principales: Gangat, Naseema, Bleeker, Jonathan, Lynch, Douglas, Olteanu, Horatiu, Letendre, Louis, Tefferi, Ayalew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521224/
https://www.ncbi.nlm.nih.gov/pubmed/35678030
http://dx.doi.org/10.3324/haematol.2022.281398
_version_ 1784799795435536384
author Gangat, Naseema
Bleeker, Jonathan
Lynch, Douglas
Olteanu, Horatiu
Letendre, Louis
Tefferi, Ayalew
author_facet Gangat, Naseema
Bleeker, Jonathan
Lynch, Douglas
Olteanu, Horatiu
Letendre, Louis
Tefferi, Ayalew
author_sort Gangat, Naseema
collection PubMed
description
format Online
Article
Text
id pubmed-9521224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-95212242022-10-24 Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia Gangat, Naseema Bleeker, Jonathan Lynch, Douglas Olteanu, Horatiu Letendre, Louis Tefferi, Ayalew Haematologica Case Report Fondazione Ferrata Storti 2022-06-09 /pmc/articles/PMC9521224/ /pubmed/35678030 http://dx.doi.org/10.3324/haematol.2022.281398 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Report
Gangat, Naseema
Bleeker, Jonathan
Lynch, Douglas
Olteanu, Horatiu
Letendre, Louis
Tefferi, Ayalew
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
title Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
title_full Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
title_fullStr Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
title_full_unstemmed Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
title_short Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
title_sort daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521224/
https://www.ncbi.nlm.nih.gov/pubmed/35678030
http://dx.doi.org/10.3324/haematol.2022.281398
work_keys_str_mv AT gangatnaseema daratumumabfortreatmentrefractoryacquiredidiopathicpureredcellaplasia
AT bleekerjonathan daratumumabfortreatmentrefractoryacquiredidiopathicpureredcellaplasia
AT lynchdouglas daratumumabfortreatmentrefractoryacquiredidiopathicpureredcellaplasia
AT olteanuhoratiu daratumumabfortreatmentrefractoryacquiredidiopathicpureredcellaplasia
AT letendrelouis daratumumabfortreatmentrefractoryacquiredidiopathicpureredcellaplasia
AT tefferiayalew daratumumabfortreatmentrefractoryacquiredidiopathicpureredcellaplasia

Ejemplares similares